company background image
A216400 logo

Invites Biocore XKON:A216400 Stock Report

Last Price

₩8.93k

Market Cap

₩68.9b

7D

-2.2%

1Y

11.6%

Updated

25 Mar, 2024

Data

Company Financials

Invites Biocore Co., Ltd.

XKON:A216400 Stock Report

Market Cap: ₩68.9b

A216400 Stock Overview

Invites Biocore Co., Ltd. provides bioanalytical and central lab services in South Korea and internationally.

A216400 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Invites Biocore Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Invites Biocore
Historical stock prices
Current Share Price₩8,930.00
52 Week High₩11,990.00
52 Week Low₩7,500.00
Beta0
1 Month Change-1.33%
3 Month Change-1.11%
1 Year Change11.63%
3 Year Change-34.58%
5 Year Change28.49%
Change since IPO-9.80%

Recent News & Updates

Recent updates

Shareholder Returns

A216400KR Life SciencesKR Market
7D-2.2%-1.5%2.1%
1Y11.6%7.8%13.4%

Return vs Industry: A216400 exceeded the KR Life Sciences industry which returned 7.5% over the past year.

Return vs Market: A216400 underperformed the KR Market which returned 13.4% over the past year.

Price Volatility

Is A216400's price volatile compared to industry and market?
A216400 volatility
A216400 Average Weekly Movement1.8%
Life Sciences Industry Average Movement7.3%
Market Average Movement5.2%
10% most volatile stocks in KR Market12.0%
10% least volatile stocks in KR Market2.4%

Stable Share Price: A216400 has not had significant price volatility in the past 3 months.

Volatility Over Time: A216400's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aHyung-Sik Choihttps://www.bio-core.com

Invites Biocore Co., Ltd. provides bioanalytical and central lab services in South Korea and internationally. It offers bioanalytical testing service during biological equivalence tests, clinical trials, toxicokinetics, nonclinical trials, vivo dynamic analysis, comparative dissolution test, and biomarker analysis; provides project strategic planning, medical translation, clinical research, quality assurance, monitoring, and data management for clinical services; and offers services, such as pharmaceutical quality control testing, emergency testing for food and drug safety, impurity testing, testing for licensed pharmaceutical products, and pharmaceutical stability testing. The company also provides disease susceptibility and anticancer drug susceptibility test; personalized genetic testing services, chromosomal microarray analysis, newborn screening, diagnostic exome sequencing, and non-invasive prenatal testing; and sequencing, microarray analysis, Real-Time PCR analysis services.

Invites Biocore Co., Ltd. Fundamentals Summary

How do Invites Biocore's earnings and revenue compare to its market cap?
A216400 fundamental statistics
Market cap₩68.86b
Earnings (TTM)₩0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A216400 income statement (TTM)
Revenue₩0
Cost of Revenue₩0
Gross Profit₩0
Other Expenses₩0
Earnings₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did A216400 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.